Current concepts and future directions for hemato-oncologic diagnostics.

Abstract

At present, hemato-oncologic diagnostics is facing dynamic changes. This applies to the exploration and introduction of novel technologies such as next-generation sequencing or digital droplet PCR for myeloid and lymphatic malignancies in laboratory routine, or liquid biopsy for patients with lymphoid malignancies. Targeted therapies such as FLT3 or IDH1/IDH2 inhibitors for acute myeloid leukemia are entering clinical practice. Thus, the demand for hematologic precision diagnostics both at initial diagnosis and during the course of the disease are equally increasing, and a short turn-around time becomes crucial. NGS expands the armamentarium for minimal residual disease diagnostics, but novel questions arise relating to sensitivity, the appropriate time points of this analysis, or the thresholds triggering therapeutic interventions. In this review article, we summarize some of the most relevant current changes and subsequent challenges for diagnostics in various myeloid and lymphatic malignancies. Future directions of hemato-oncologic diagnostics in the next 5-10 years are highlighted.

• Authors: Johanna Flach, Evgenii Shumilov, Raphael Joncourt, Naomi Porret, Urban Novak, Thomas Pabst, Ulrike Bacher
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 151 Pg. 102977 (Jul 2020) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 32446181 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Topics

• Diagnostic Tests, Routine (trends)
• Genetic Testing (methods, trends)
• Genomics (methods)
• Hematologic Neoplasms (diagnosis)
• High-Throughput Nucleotide Sequencing (methods)
• Humans
• Leukemia, Myeloid, Acute (diagnosis, genetics)
• Mutation
• Myelodysplastic Syndromes (diagnosis, genetics)
• Neoplasm, Residual
• Precision Medicine (trends)